Jasper Therapeutics grants options to director
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Jasper Therapeutics, Inc. reported that director Kurt Von Emster received a grant of stock options covering 7,500 shares of Voting Common Stock at an exercise price of $0.6300 per share. The options were granted automatically under the Non-Employee Director Compensation Policy, vest on July 31, 2027, and expire on July 31, 2036.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy F1 | 7,500 | $0.00 | $0.00 |
Footnotes (1)
- F1. Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date.
Key Figures
Key Terms
Non-Employee Director Compensation Policy financial
stock option financial
vesting financial
conversion_or_exercise_price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stock options were granted to Jasper Therapeutics (JSPR) director Kurt Von Emster?
What is the exercise price of the new JSPR director stock options?
When do Kurt Von Emster's new Jasper Therapeutics (JSPR) options vest and expire?
Under what policy were the JSPR director stock options granted?
Were the new JSPR director options granted under a Rule 10b5-1 trading plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.